info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)

Henry Schein Increases its Portfolio in Several of Dentistry's Fastest-growing Categories, Including Clinical Software, Oral Surgery, and Orthodontic Products

By Rahul Gotadki , 21 December, 2022

The shareholders of Biotech Dental S.A.S., a rapidly expanding provider of cutting-edge clinical software and oral surgery and orthodontic products based in Salon-de-Provence, France, have signed a definitive agreement with Henry Schein, Inc., the world's largest provider of health care solutions to office-based medical and dental professionals, to acquire a major share stake in the business.

Henry Schein and Biotech Dental will expand the number of dentists, dental labs, and geographic areas that have access to Biotech Dental's complete line of high-quality software, products, and services, including dental prostheses, clear aligners, dental implants, regenerative solutions, and biomaterials. This transaction's implementation is dependent on receiving certain regulatory approvals.

Nemotec, a complete, integrated suite of planning and diagnostic software using an open architecture that connects dispersed devices to provide a digital view of the patient's overall health condition, offering greater diagnostic accuracy and an enhanced care experience, is one of several effective solutions supplied by Biotech Dental. In addition to producing the Smilers® brand of clear aligners, Biotech Dental is one of the brands with the fastest growth in France for custom abutments and implants. Moreover, LaGalaxy, a comprehensive, open, and secure software platform where both clinical and administrative procedures can be carried out, has been developed by Biotech Dental. Dentists and dentistry labs have access to end-to-end integrated technological platforms on a single platform that cut the price of implants, orthodontic, and prosthetic treatments while reducing treatment times and costs and helping to enhance case outcomes.

In accordance with the terms of the deal, Henry Schein will acquire a controlling interest in Biotech Dental. The remaining minority stake in the business will stay under the ownership of Upper side Capital Partners Group. The revenue for Biotech Dental's fiscal year 2021 was over $100 million. When amortization is not considered, Henry Schein anticipates that this deal will marginally erode 2023 profits per share. Non-cash acquisition accounting adjustments for inventories are the leading cause of the dilution. Financial information wasn’t publicly disclosed.
 

                Dental Implants Placed By General Practitioners Vs. Specialists in the US         

Placement.jpg

Latest News

2025.png
Quadric and Denso Team Up to Progress Automotive AI Semiconductors for 2025

The automotive industry will benefit significantly from strategic partnerships in artificial intelligence (AI) and its use in cars. AI integration into automobiles is projected to improve considerably in the year 2025 due to the formation of various…

Read More

2024.png
Semiconductor Trade Restrictions Threaten EV, AI, and Industrial Progress in 2025

In 2025, the global semiconductor industry is already grappling with new and complex challenges emanating from the trade wars and policy changes between the United States and China. The semiconductor industry, an essential backbone of technology…

Read More

2030.png
Surge in Demand for Semiconductors in 2025 Driven by Boom of Generative AI

The rapid use of generative artificial intelligence (AI) in 2025 has profoundly affected the semiconductor sector, resulting in unprecedented growth for advanced chip technologies. According to estimates made by the Capgemini Research Institute, this…

Read More

condition.png
Texas Faces Challenges to Balance Grid Security and AI Boom in 2025

Texas will face an emerging challenge in 2025 as the electricity grid experiences unprecedented strain from the rapid expansion of artificial intelligence (AI) data centers. Power usage has increased due to technology firms' indiscriminate placement…

Read More

Stocks.png
Tech Turmoil in 2025: Magnificent Seven Stocks Slide as Tesla Leads Market Decline

With the "Magnificent Seven”- Apple, Microsoft, Amazon, Alphabet, Meta, Nvidia, and Tesla leading the fall, the US stock market saw a significant dip in early 2025. Usually seen as market drivers, these IT behemoths found themselves in the correction…

Read More

Author Pic
Rahul Gotadki

Assistant Manager